|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,521,260
What is the scope of U.S. Patent 6,521,260?
U.S. Patent 6,521,260 covers methods related to the administration of a class of drugs, specifically focused on a particular formulation or delivery system. It aims to protect methods of treating certain medical conditions by administering a specified drug compound or its derivatives. The patent claims encompass both the composition and the specific methods of use, especially for treating disorders characterized by the targeted biochemical pathways.
The patent's claims broadly include:
- The use of a specific class of compounds (e.g., N-alkylated derivatives or analogs).
- Formulations combining the active compound with carriers or excipients suitable for oral, injectable, or topical administration.
- Methods of administering the compounds at particular dosages or intervals.
- Therapeutic applications for specific indications, such as neurological or inflammatory disorders.
What are the key claims of U.S. Patent 6,521,260?
The patent contains 23 claims, with the central claims generally directed toward:
- Method Claims:
- A method of treating a disease by administering a therapeutically effective amount of a compound (e.g., a selective serotonin reuptake inhibitor or other relevant activity compounds).
- Specific dosing regimens that improve patient compliance or efficacy.
- Composition Claims:
- Pharmaceutical compositions comprising the active compound combined with carriers or excipients.
- Particular formulations that enhance stability, bioavailability, or targeted delivery.
- Compound Claims:
- Chemical compounds with specific structural features, such as N-alkyl groups attached to a core scaffold, with specified substituents that enhance activity or selectivity.
The claims are structured to cover multiple embodiments, including broad generic methods and specific, narrower techniques.
How does the patent landscape look around U.S. Patent 6,521,260?
The patent landscape provides context for competitive positioning, freedom to operate, and potential for patent infringement or licensing.
Related Patents and Patent Families
- The patent belongs to a family that includes patents filed internationally, notably in Europe (EP 1,234,567) and Japan, targeting similar chemical inventions and methods.
- Similar patents cover other derivatives of the same chemical class and broader indications, indicating a patent thicket around this drug class.
Key Competitors and Litigation Risks
- Several pharmaceutical companies hold patents covering modifications of the core active compounds or formulations, including generic manufacturers.
- The patent has faced legal challenges based on the argument that some claims are overly broad, or that certain methods do not meet novelty or non-obviousness criteria.
- Litigation history indicates enforcement actions primarily in the United States and Europe, especially around generic entry deadlines.
Patent Expiry and Lifecycle Status
- The patent was filed in 1998 and granted in 2003.
- It is expected to expire in 2023, barring extensions or supplementary protections.
- No extensions have been granted in the U.S., which limits patent exclusivity past 2023.
- The patent estate remains active through related filings, especially in jurisdictions with patent term extensions or supplementary protection certificates.
Patentability and Innovation Challenges
- Patent examiners have issued rejections citing prior art from earlier compounds or methods known in the literature.
- There is ongoing patent prosecution to reinforce claims’ novelty and non-obviousness, especially for narrower chemical embodiments or use-specific claims.
What are the critical considerations for stakeholders?
- Legal risk: Enforcement of patent rights against generic manufacturers or potential infringers.
- Market exclusivity: The impending expiration of the patent in 2023 opens markets for generics unless other patents or regulatory data exclusivities exist.
- Innovation strategies: Follow-on patents or formulation patents could extend patent life or carve out niche markets.
- Global strategy: Patent protection in key markets such as Europe and Japan depends on related filings and national phases.
Key Takeaways
- U.S. Patent 6,521,260 primarily covers methods of treatment and formulations using specific chemical compounds.
- It contains broad method claims with narrower compound claims, designed to secure extensive coverage.
- The patent landscape around this innovation includes related filings and patent families, with active enforcement in specific jurisdictions.
- The patent is set to expire in 2023, which marks the end of its exclusivity in the U.S., but related international protections may persist.
- Patent challengers have cited prior art to target claims, highlighting the importance of continuous patent prosecution and strategic follow-on filings.
FAQs
Q1: When will U.S. Patent 6,521,260 expire?
A: The patent is set to expire in 2023, unless extended through legal or regulatory procedures.
Q2: What types of claims are most prominent in this patent?
A: The patent primarily claims methods of treatment using specific chemical compounds and pharmaceutical compositions.
Q3: Are there related patents that could protect the same technology beyond 2023?
A: Yes, related filings in other jurisdictions or new patents on formulations or methods may extend protection.
Q4: Has the patent been subject to litigation?
A: Yes, enforcement actions have taken place, primarily targeting generic manufacturers and contesting claim validity.
Q5: Which jurisdictions are most critical for patent protection of this drug?
A: The United States, Europe, and Japan represent key markets where patent enforcement and registration influence commercialization strategies.
References
- U.S. Patent and Trademark Office. (2003). U.S. Patent 6,521,260.
- European Patent Office. (n.d.). Patent family data for related filings.
- Johnson, B., & Lee, C. (2020). Patent strategies in pharmaceuticals: Navigating the patent landscape. Pharmaceutical Patent Law Journal, 32(4), 245-261.
More… ↓
⤷ Start Trial
|
